Yifan Pharmaceutical saw no growth in patent filings and highest growth of 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Yifan Pharmaceutical’s patent filings and grants. Buy the databook here.
Yifan Pharmaceutical has been focused on protecting inventions in China(CN) with two publications in Q2 2024
The China(CN) Patent Office dominates the patent grants with nearly 100% of grants. The China(CN) patent Office are among the top ten patent offices where Yifan Pharmaceutical is filings its patents. Among the top granted patent authorities, Yifan Pharmaceutical has 100% of its grants in China(CN).
Patents related to industrial automation lead Yifan Pharmaceutical's portfolio
Yifan Pharmaceutical has the highest number of patents in industrial automation. For industrial automation no patents were filed and 100% of patents were granted in Q2 2024.
Sterilisation related patents lead Yifan Pharmaceutical portfolio
Yifan Pharmaceutical has highest number of patents in sterilisation.
For comprehensive analysis of Yifan Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.